An update on the pharmacogenomics of metformin: progress, problems and potential

Molecular mechanism of action of metformin: old or new insights?

(2013) Graham Rena et al.   DIABETOLOGIA

Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP

(2013) Russell A. Miller et al.   NATURE

A gene–gene interaction between polymorphisms in the OCT2 and MATE1 genes influences the renal clearance of metformin

(2013) Mette M.H. Christensen et al.   Pharmacogenetics and Genomics

The Effect of Novel Promoter Variants in MATE1 and MATE2 on the Pharmacokinetics and Pharmacodynamics of Metformin

(2012) S L Stocker et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2012) S. E. Inzucchi et al.   DIABETES CARE

Pharmacogenomic association between a variant inSLC47A1gene and therapeutic response to metformin in type 2 diabetes

(2012) I. Tkáč et al.   DIABETES OBESITY & METABOLISM

The role of ATM in response to metformin treatment and activation of AMPK

(2012) Sook Wah Yee et al.   NATURE GENETICS

Metformin pathways

(2012) Li Gong et al.   Pharmacogenetics and Genomics

Association of genetic variation in the organic cation transporters OCT1, OCT2 and multidrug and toxin extrusion 1 transporter protein genes with the gastrointestinal side effects and lower BMI in metformin-treated type 2 diabetes patients

(2012) Linda Tarasova et al.   Pharmacogenetics and Genomics

Serine racemase rs391300 G/A polymorphism influences the therapeutic efficacy of metformin in Chinese patients with diabetes mellitus type 2

(2011) Min Dong et al.   CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY

Clinical Pharmacokinetics of Metformin

(2011) Garry G. Graham et al.   CLINICAL PHARMACOKINETICS

A Common 5′-UTR Variant in MATE2-K Is Associated With Poor Response to Metformin

(2011) J H Choi et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Cellular and molecular mechanisms of metformin: an overview

(2011) Benoit Viollet et al.   CLINICAL SCIENCE

Metformin activates AMP-activated protein kinase in primary human hepatocytes by decreasing cellular energy status

(2011) X. Stephenne et al.   DIABETOLOGIA

National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants

(2011) Goodarz Danaei et al.   LANCET

The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c

(2011) Mette M.H. Christensen et al.   Pharmacogenetics and Genomics

Use of Cells Expressing γ Subunit Variants to Identify Diverse Mechanisms of AMPK Activation

(2010) Simon A. Hawley et al.   Cell Metabolism

Common Variants in 40 Genes Assessed for Diabetes Incidence and Response to Metformin and Lifestyle Intervention in the Diabetes Prevention Program

(2010) K. A. Jablonski et al.   DIABETES

Pharmacological Treatment of the Pathogenetic Defects in Type 2 Diabetes: The randomized multicenter South Danish Diabetes Study

(2010) J. Gram et al.   DIABETES CARE

Organic Cation Transporter 1 Polymorphisms Predict the Metabolic Response to Metformin in Women with the Polycystic Ovary Syndrome

(2010) Alessandra Gambineri et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state

(2010) Marc Foretz et al.   JOURNAL OF CLINICAL INVESTIGATION

Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes

(2010) Kaixin Zhou et al.   NATURE GENETICS

OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine

(2010) Zhi-Jun Wang et al.   Pharmacogenetics and Genomics

Heterozygous variants of multidrug and toxin extrusions (MATE1 and MATE2-K) have little influence on the disposition of metformin in diabetic patients

(2010) Kana Toyama et al.   Pharmacogenetics and Genomics

Role of organic cation transporter 3 (SLC22A3) and its missense variants in the pharmacologic action of metformin

(2010) Ligong Chen et al.   Pharmacogenetics and Genomics

The Effects of Genetic Polymorphisms in the Organic Cation Transporters OCT1, OCT2, and OCT3 on the Renal Clearance of Metformin

(2009) M V Tzvetkov et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Reduced-Function SLC22A1 Polymorphisms Encoding Organic Cation Transporter 1 and Glycemic Response to Metformin: A GoDARTS Study

(2009) K. Zhou et al.   DIABETES

Genetic Variation in the Multidrug and Toxin Extrusion 1 Transporter Protein Influences the Glucose-Lowering Effect of Metformin in Patients With Diabetes: A Preliminary Study

(2009) M. L. Becker et al.   DIABETES

Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver

(2009) Anne T. Nies et al.   HEPATOLOGY

Identification of multidrug and toxin extrusion (MATE1 and MATE2-K) variants with complete loss of transport activity

(2009) Moto Kajiwara et al.   JOURNAL OF HUMAN GENETICS

Identification and characterization of novel polymorphisms in the basal promoter of the human transporter, MATE1

(2009) Ji Ha Choi et al.   Pharmacogenetics and Genomics

Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin

(2009) Ying Chen et al.   Pharmacogenetics and Genomics

Genetic variants in multidrug and toxic compound extrusion-1, hMATE1, alter transport function

(2009) Ying Chen et al.   PHARMACOGENOMICS JOURNAL

Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus

(2009) M L Becker et al.   PHARMACOGENOMICS JOURNAL

Genetic Variants of the Organic Cation Transporter 2 Influence the Disposition of Metformin

(2008) IS Song et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Polymorphism in human organic cation transporters and metformin action

(2008) Hiroshi Takane et al.   PHARMACOGENOMICS

Ovulatory Response to Treatment of Polycystic Ovary Syndrome Is Associated with a Polymorphism in theSTK11Gene

(2007) Richard S. Legro et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM